1. Scrip
  2. >>Business
  3. >>Deals

Sanofi Nabs Kymera IRAK4 Protein Degrader As It Continues To Build In I&I

 
• By Jessica Merrill

Kymera will receive $150m upfront from Sanofi in a deal the big pharma views as an opportunity to develop a breakthrough oral drug for atopic dermatitis and other conditions.

Wooden little men holding hands on wooden boards background. Symbol of friendship, love and teamwork
Sanofi and Kymera partnered on a protein degrader for immunology and inflammation • Source: Shutterstock

Sanofi is partnering with Kymera Therapeutics, LLC. in a budding area of drug development – protein degradation – as it looks for new opportunities to expand in immunology and inflammation. The companies announced a collaboration on 9 July in which Sanofi agreed to pay Kymera $150m up front for rights to develop and commercialize first-in-class protein degrader therapies targeting interleukin-1 receptor associated kinase 4 (IRAK4) in patients with immune-inflammatory diseases and a second earlier-stage program.

In addition to the upfront payment, Sanofi also agreed to pay more than $2bn in potential development, regulatory and sales milestone fees as well as royalties on sales.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

 
• By Dexter Jie Yan

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race

 
• By Jessica Merrill

Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Bristol Will Pay BioNTech $1.5bn Up Front To Enter PD-L1xVEGF Space

 
• By Joseph Haas

BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.

More from Business

Bristol Will Pay BioNTech $1.5bn Up Front To Enter PD-L1xVEGF Space

 
• By Joseph Haas

BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

 
• By Jessica Merrill

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.